Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial

被引：0

作者：

Smith, B. Douglas ^{[1
]}

Cortes, Jorge E. ^{[2
]}

Rea, Delphine ^{[3
]}

Mauro, Michael J. ^{[4
]}

Patwardhan, Pallavi ^{[5
]}

Maegawa, Rodrigo ^{[5
]}

Zacker, Christopher ^{[5
]}

Corbin, Regina ^{[5
]}

Keeping, Sam ^{[6
]}

Sasaki, Koji ^{[7
]}

机构：

[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[2] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA

[3] Hop St Louis, AP HP, Dept Hematol, Paris, France

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Novartis Pharmaceut, E Hanover, NJ USA

[6] PRECISIONheor, Vancouver, BC, Canada

[7] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

CML; chronic myeloid leukemia; health care resource use; asciminib; bosutinib; tyrosine kinase inhibitor;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-353

引用

页码：S334 / S334

页数：1

共 31 条

[1] A Multicenter, Randomized Phase 3 Study of Asciminib (ABL001) vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 TKIs
Mauro, Michael J.
Hochhaus, Andreas
Boquimpani, Carla
Minami, Yosuke
Allepuz, Alex
Polydoros, Fotis
Bedoucha, Veronique
Aimone, Paola
Rea, Delphine
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S286 - S287
[2] ASCEMBL Phase 3 Health-Related Quality of Life (HRQL) Comparison of Asciminib and Bosutinib for Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2 or More Tyrosine Kinase Inhibitors (TKI)
Mauro, Michael J.
Boquimpani, Carla
Rea, Delphine
Hochhaus, Andreas
Maheshwari, Vikalp Kumar
Allepuz, Alex
Patwardhan, Pallavi
Wu, Ying
DeRosa, Michael
Minami, Yosuke
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S336 - S336
[3] Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After.2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update
Rea, Delphine
Hochhaus, Andreas
Mauro, Michael J.
Minami, Yosuke
Lomaia, Elza
Voloshin, Sergey
Turkina, Anna
Kim, Wook
Apperley, Jane F.
Cortes, Jorge E.
Abdo, Andre
Fogliatto, Laura Marie
Kim, Dennis Dong Hwan
le Coutre, Philipp
Saussele, Susanne
Annunziata, Mario
Hughes, Timothy P.
Chaudhri, Naeem
Chee, Lynette
Garcia-Gutierrez, Valentin
Sasaki, Koji
Kapoor, Shruti
Allepuz, Alex
Quenet, Sara
Bedoucha, Veronique
Boquimpani, Carla
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S295 - S296
[4] Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study
Mauro, Michael
Hochhaus, Andreas
Hughes, Timothy
Rea, Delphine
Boquimpani, Carla
Minami, Yosuke
Apperley, Jane
Garcia-Gutierrez, Valentin
Kapoor, Shruti
Espurz, Noemi
Dhamal, Vishal
Cortes, Jorge
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S340 - S340
[5] Efficacy and Safety of Asciminib in Heavily Pretreated Patients with Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Sensitivity to Tyrosine Kinase Inhibitors (TKIs)
Hughes, Timothy
Mauro, Michael
Kim, Dong-Wook
Cortes, Jorge
Rea, Delphine
Minami, Hironobu
Breccia, Massimo
DeAngelo, Daniel
Hochhaus, Andreas
Goh, Yeow-Tee
le Coutre, Philipp
Lang, Fabian
Cacciatore, Silvia
Aimone, Paola
Stenson, Laura
Polydoros, Fotis
Talpaz, Moshe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S235 - S235
[6] Health care resource utilization in 3L+patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib
Cortes, Jorge E.
Rea, Delphine
Mauro, Michael J.
Tran, Diana
Wang, Pearl
Jadhav, Kejal
Yocolly, Aurore
Sasaki, Koji
JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 915 - 923
[7] Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study
Minami, Yosuke
Doki, Noriko
Matsuoka, Hiroshi
Yokota, Takafumi
Tomita, Akihiro
Takahashi, Naoto
Kubo, Kohmei
Goto, Tatsunori
Kirito, Keita
Maki, Akio
Aoki, Makoto
Dawson, Meryem Ktiouet
Matsumura, Itaru
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (03) : 305 - 313
[8] Tolerability of Asciminib vs Investigator-Selected (IS) Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 ASC4FIRST Study in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Issa, Ghayas C.
Larson, Richard A.
Hughes, Timothy P.
Hochhaus, Andreas
Takahashi, Naoto
Bombaci, Felice
Wang, Jianxiang
Kim, Dong-Wook
Dong, Dennis
Kim, Hwan
Gu, Ennan
Zhang, Yifan
Kapoor, Shruti
Agrawal, Nithya
Jinwal, Rajendra
Damon, Andrea
Sadek, Islam
Cortes, Jorge E.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S368 - S368
[9] Does platelet aggregation differ among chronic myeloid leukemia-chronic phase (CML-CP) patients on tyrosine kinase inhibitors (TKIs)? A tertiary center experience
Moeen, Sawsan M.
Afifi, Ola A.
Thabet, Ahmad F.
Saleh, Medhat A.
Morad, Mohamed A.
EGYPTIAN JOURNAL OF HAEMATOLOGY, 2023, 48 (02) : 185 - 190
[10] ASC4KIDS: A Multicenter, Open-Label, Phase 1b/2 Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Hijiya, Nobuko
Heneghan, Mallorie
Kapoor, Shruti
Dhamal, Vishal
Hoch, Matthias
Descamps, Laurence
Cardoso, Ana Paula
Pollard, Jessica
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S346 - S347

← 1 2 3 4 →